The Immunogenicity Database Collaborative (IDC): A Standardized, Publicly Available Database for Clinical Immunogenicity Observations and Insights

The incidence and impact of anti-drug antibodies (ADAs) against biotherapeutics remain difficult to predict, limiting efforts to mitigate immunogenicity risk prior to clinical trials. Existing data are fragmented across disparate sources with inconsistent definitions, representing a key barrier to progress in the field. Here, we present the Immunogenicity Database Collaborative (IDC) and its release of the Immunogenicity Database (DB) V1: a structured clinical immunogenicity dataset integrating therapeutic characteristics, sequence, and patient cohort-level data from publicly available sources. The dataset includes 4,146 ADA datapoints, 1,788 cohorts, 727 clinical trials and 218 therapeutics. We highlight trends in ADA incidence, evaluate sources of variability, and identify driving factors of immunogenicity risk. This work provides a foundational resource to standardize and support immunogenicity risk assessment across the industry. It also provides an initial data architecture and invites the research community to contribute towards future expansions of the database into key areas of interest to the field.